In addition to the previously reported antitumor activity in acute myeloid leukemia, LSD1 inhibitors have shown lineage‐specific activity in SCLC cell lines and patient‐derived xenograft models [5, 6, 13, 14, 15]. This evidence concerns the gene KDM1A and small cell lung carcinoma.